To the Editor: A 39-year-old man presented with progressive limb atrophy and weakness. The patient had generalized muscular hypotonia at birth; he could not run well in elementary school. Neurologic examination revealed atrophy of the facial muscles and limited left eye adduction. In the upper limbs, the patients showed proximal muscle atrophy and weakness (Figure 1A), while in the lower extremities, the weakness was more prominent distally than proximally. Neither spontaneous or percussion myotonia nor muscle hypertrophy was observed.

Serum creatine kinase was mildly elevated, 223 IU/L (normal value < 170). In the electrophysiologic examinations, motor and sensory conduction studies were normal; needle electromyogram showed fibrillation and positive sharp waves; in addition, numerous myotonic discharges were noted, and they waxed and waned with variations in amplitude and frequency [Figure 1B]. Motor unit potentials of the first dorsal interosseous, tibialis anterior, and quadriceps femoris were of short duration and low amplitude, with early recruitments.

Muscle biopsy from the left biceps brachii showed central nuclei in almost all muscle fibers. Nicotinamide dehydrogenase tetrazolium reductase staining revealed increased perinuclear oxidative activity and sarcoplasmic strands radiating from the central nucleus conferring a spoke-like appearance, which was also observed in immunohistochemical desmin and vimentin staining [Figure 1 C–F].

Genetic evaluation revealed a heterozygous c.1565G>A substitution in dynamin 2 (DNM2) [Figure 1G], resulting in R522H amino acid change in dynamin-2, which was previously reported to be pathogenic.[1,2] The patient’s parents showed no variations in this nucleotide site, revealing that the patient carried a de novo mutation.

Mutations in DNM2 are rare, and have been found to be associated with centronuclear myopathy (CNM) and Charcot-Marie-Tooth disease.[1] Our patient had ophthalmoparesis, facial and limb atrophy, and weakness, and electrophysiologic study showed myogenic impairment without nerve conduction abnormalities, revealing a pure CNM phenotype.

Myotonia is a defining clinical symptom and sign common to a relatively small group of muscle diseases, including the myotonic dystrophies and the non-dystrophic myotonic disorders. Myotonic discharge without clinical myotonia can be seen in polymyositis, acid maltase deficiency, and so on.[3] In 1978, Gil-Peralta et al.[4] firstly reported clinical myotonia in a case of CNM, while during the same period, CNM cases with electrical myotonia have been reported. Although these cases had no genetic tests to identify the causal gene, they were distinct from dystrophic myotonia due to the clinical and pathologic presentations. In 2018, Stino and Iyadurai reported a patient presenting electrical but not clinical myotonia, carrying the same mutation (R522H) on the DNM2 gene; however, the patient did not undergo muscle biopsy evaluation.[1] It is worth noting that the same mutation has also been reported in two CNM patient cohorts, who showed neither clinical nor electrical myotonia.[2,3]

In summary, our study further confirms that DNM2-related CNM may present electrical without clinical myotonia. According to the function of DNM2 protein and the morphologic change in immunohistochemical desmin and vimentin staining, we presume that the
myotonia may result from the impairment of cytoskeleton networks and membrane modulation. Further study is needed to clarify the mechanism of the myotonic discharge of DNM2-related CNM.

**Declaration of patient consent**

The authors certify that they have obtained the appropriate patient consent form. In the form, the patient provided his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and that due efforts will be made to conceal his identity but that anonymity cannot be guaranteed.

**Conflicts of interest**

None.

**References**

1. Stino AM, Iyadurai SJ. Dynamin-2-associated myopathy with electrical but not clinical myotonia. Muscle Nerve 2018;57:E118–E120. doi: 10.1002/mus.26006.
2. Chen T, Pu C, Wang Q, Liu J, Mao Y, Shi Q. Clinical, pathological, and genetic features of dynamin-2-related centronuclear myopathy in China. Neurol Sci 2015;36:735–741. doi: 10.1007/s10072-014-2028-6.
3. Heatwole CR, Statland JM, Logigian EL. The diagnosis and treatment of myotonic disorders. Muscle Nerve 2013;47:632–648. doi: 10.1002/mus.23683.
4. Gil-Peralta A, Rafel E, Bautista J, Alberca R. Myotonia in centronuclear myopathy. J Neurol Neurosurg Psychiatry 1978;41:1102–1108. doi: 10.1136/jnnp.41.12.1102.
5. Susman RD, Quijano-Roy S, Yang N, Webster R, Clarke NF, Dowling J, et al. Expanding the clinical, pathological and MRI phenotype of DNM2-related centronuclear myopathy. Neuromuscul Disord 2010;20:229–237. doi: 10.1016/j.nmd.2010.02.016.

How to cite this article: Huang X, Liu XY, Chen L, Sun AP, Zhang YS, Zheng DF, Zhong YF, Fan DS. A case of de novo dynamin 2-related centronuclear myopathy with electrical but not clinical myotonia. Chin Med J 2020;133:3023–3024. doi: 10.1097/CM9.0000000000009974.